Sidley is acting as lead counsel for the debtor in the Chapter 11 protection filing of Tricida Inc., a clinical-stage pharmaceutical company focused on the goal of slowing the progression of chronic kidney disease through the treatment of metabolic acidosis by an investigational drug candidate, Veverimer (also known as TRC101). Tricida filed for Chapter 11 protection on Wednesday, January 11 in the Bankruptcy Court for the District of Delaware. The filing lists US$100–US$500 million in liabilities, including approximately US$200 million in principal funded debt under its convertible notes.
The team is led by Restructuring partners Sam Newman (Los Angeles) and Charles Persons (Dallas), with Corporate partners Geoff Levin and Chaim Theil (both New York) and Litigation partners Sara Brody and Sarah Hemmendinger (both San Francisco). The team also includes Jeri Leigh Miller (senior managing associate, Restructuring), Cammie Teo (senior managing associate, Corporate), Julia Philips Roth (managing associate, Restructuring), Michael Sabino (managing associate, Restructuring), Kyle Fong (associate, Corporate), Jerry Ford (associate, Corporate), and Chelsea McManus (associate, Restructuring).
The team is led by Restructuring partners Sam Newman (Los Angeles) and Charles Persons (Dallas), with Corporate partners Geoff Levin and Chaim Theil (both New York) and Litigation partners Sara Brody and Sarah Hemmendinger (both San Francisco). The team also includes Jeri Leigh Miller (senior managing associate, Restructuring), Cammie Teo (senior managing associate, Corporate), Julia Philips Roth (managing associate, Restructuring), Michael Sabino (managing associate, Restructuring), Kyle Fong (associate, Corporate), Jerry Ford (associate, Corporate), and Chelsea McManus (associate, Restructuring).
